How editing two genes at once boosts CAR-T therapy

Dropping two brakes at once

What if stopping cancer meant letting go of two brakes rather than pressing harder on the gas? In CAR-T therapy, doctors take a patient's own immune T cells and alter them to hunt tumours. These engineered cells often run out of steam. That happens because intracellular checkpoints—internal brakes inside an immune cell—switch them off too soon.

Think of driving a car with two handbrakes pulled tight. Releasing one brake helps a little. Taking off both at once lets the car keep moving at full speed without stalling.

Testing gene pairs in living models

To find the best fix, researchers ran a high-throughput CRISPR screen directly inside living models. A CRISPR screen is a lab tool that tests many gene edits at once. The team tested double-knockout edits, which turn off two genes at the exact same time. Single gene edits gave small boosts. Pairs worked together far better than expected.

The top pair was NR4A1 and SOCS3. When the team checked the cells with single-cell RNA sequencing, they saw key energy-building pathways switch on. This double edit sparked higher mitochondrial activity—the cell's way of generating fuel to stay alive. The extra fuel gave the T cells the power to fight tumours over long stretches. Across several tumour models, this pair beat standard single-gene and double-gene edits while keeping normal cell control in place.

What we still do not know

These findings offer a fresh blueprint for building stronger cell treatments. Even so, the study looked only at lab tumour models. It does not prove that this edit is safe or works well in human patients.

Researchers also do not yet know the exact molecular path that links the loss of both genes to this rise in cell fuel. Human trials will be needed to see if this double edit works in our bodies.